Last reviewed · How we verify
NCT05368883
Comparison of Different Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis
NA trial testing Exercise- One-Legged in Pulmonary Sarcoidosis in 26 participants. Completed in 1 September 2024.
21 April 2023
Quick facts
| Lead sponsor | Istanbul University - Cerrahpasa |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 1 March 2023 |
| Primary completion | 21 April 2023 |
| Estimated completion | 1 September 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Exercise- One-Legged
- Exercise-Two-Legged
Conditions studied
- Pulmonary Sarcoidosis — all drugs for Pulmonary Sarcoidosis →
Sponsor
Istanbul University - Cerrahpasa
Who can join
Adults 20 to 65, female only, with Pulmonary Sarcoidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pulmonary rehabilitation is a key element in the management of people with chronic respiratory disease. A properly followed supervised physical training program in sarcoidosis is safe and has no absolute contraindications. Fatigue can also be associated with sarcoidosis for different reasons. Individualized rehabilitation training can improve the symptoms of patients with sarcoidosis. There is no study in the literature investigating the effectiveness of one-legged exercises that reduce peripheral muscle use, in patients with sarcoidosis. In our study, these two exercise methods will be compared by applying one-legged exercise training and two-legged exercise training. The effect of one-legged exercise training on exercise capacity and fatigue in sarcoidosis patients will be examined. The primary aim of our study is to compare the effects of one-legged exercise training, which is a current exercise approach, and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. The secondary aim is to examine the effect of this exercise training on peripheral muscle strength and quality of life parameters.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05368883
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Sarcoidosis
Currently open trials in the same condition.
- NCT06853834 — Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis · NA · recruiting
- NCT05415137 — Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis · Phase 3 · active not recruiting
- NCT00001532 — Role of Genetic Factors in the Development of Lung Disease · recruiting
Other Istanbul University - Cerrahpasa trials
Trials by the same sponsor.
- NCT07588685 — Validity and Reliability of the Turkish Form of the Enjoyment of Physical Activity Scale-8 in Geriatrics With Minimal Co · not yet recruiting
- NCT07370025 — The Effect of Lullaby During Bath Time on Mother-Infant Bonding, Postpartum Depression, and Parental Self-Efficacy in In · NA · not yet recruiting
- NCT07378449 — The Effect of Hand Exercise Hoops on Labour Pain · NA · not yet recruiting
- NCT07293000 — Evaluating Two Nursing Interventions to Prevent Urinary Retention After Spinal Anesthesia · NA · not yet recruiting
- NCT07562880 — Validity and Reliability of the Exercise-Related Health Beliefs Attitude Scale in Geriatric Individuals · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05368883 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul University - Cerrahpasa
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05368883.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing